Skip to content

MeiraGTx Holdings plc MGTX Change in fair value of contingent consideration

Change in fair value of contingent consideration at other companies

Beam Therapeutics logo
Beam TherapeuticsBEAM
-$514K-2,004%

Other financials

Income statement

See full
Revenue$293.0K-84.8%
Operating income-$40.8M+1.9%
Net income-$46.3M-15.8%
EPS (diluted)-$0.57-11.8%

Balance sheet

See full
Cash & equivalents$71.5M+7.5%
Total debt$62.7M-22.5%
Total equity-$58.1M-276%
Total assets$244.7M+9.2%

Cash flow

See full
Operating cash flow$17.8M+148%
CapEx$2.0M+17.4%
Free cash flow$15.8M+141%

Valuation

See full
Market cap$1.07B+111%
Enterprise value$1.07B+103%
P/S13.5×-1.3×

Profitability

See full
Operating margin-597.9%-207pp
Net margin-615.3%
FCF margin-441.5%-126pp

Returns & leverage

See full
Return on equity-379.5%
Debt / equity27.2×+26.1×
Current ratio0.5×-1.0×

Where this comes from

Reported directly by MeiraGTx Holdings plc in its filing.

Tagged under the XBRL concept us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration.

The official record: MeiraGTx Holdings plc’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about MeiraGTx Holdings plc's change in fair value of contingent consideration.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MeiraGTx Holdings plc's change in fair value of contingent consideration?
MeiraGTx Holdings plc (MGTX) reported change in fair value of contingent consideration of $920K in Q1 2026.
How has MeiraGTx Holdings plc's change in fair value of contingent consideration changed year-over-year?
MeiraGTx Holdings plc's change in fair value of contingent consideration increased by 49.6% year-over-year, from $615K to $920K.
What does change in fair value of contingent consideration mean?
Reflects the non-cash adjustment to the fair value of liabilities related to potential future payments for past acquisitions, typically triggered by clinical or regulatory milestones. For biotech firms, this adjustment reflects changes in the probability or timing of achieving development goals. It provides insight into the long-term financial obligations tied to the success of acquired pipeline assets.